logo-loader
HealthPharma & Biotech
viewArecor

Arecor given green light to begin Phase I trial of AT247 diabetes treatment

The study will compare the AT247’s pharmacokinetic and pharmacodynamic profiles with two current best in class products - Novo Nordisk’s Novolog and Fiasp

diabetes
A company’s clinical trial application has to be approved by regulators before the study can begin

Arecor has been given the green light from Austrian regulators to begin a Phase I trial of its AT247 Type I diabetes treatment.

The Austrian Federal Office for Safety in Health Car (BASG) has approved Arecor’s Phase I clinical trial application (CTA).

READ: Arecor appoints Susan Lowther as new CFO

“We are pleased that the CTA has been approved to enable a clinical study of AT247,” said chief executive Sarah Howell.

“We believe that this product candidate meets a recognised need to develop faster-acting insulins to further improve the lives of people managing Type I diabetes.”

She added; “This is an important milestone for Arecor and we look forward to providing further updates as AT247 progresses through clinical development.”

AT247 is an injection designed to speed up the absorption of glucose after eating and generates a physiological response more like that of a healthy person.

The study will compare the drug’s pharmacokinetic and pharmacodynamic profiles with two current best in class products - Novo Nordisk’s Novolog and Fiasp. It will also assess the safety and efficacy aspects.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arecor named herein, including the promotion by the Company of Arecor in any Content on the Site, the Company receives from said issuer annual...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read